{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T07:59:40Z","timestamp":1792223980584,"version":"4.4.0"},"reference-count":57,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T00:00:00Z","timestamp":1359590400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0054826","type":"journal-article","created":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T22:28:46Z","timestamp":1359671326000},"page":"e54826","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":80,"title":["mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms"],"prefix":"10.1371","volume":"8","author":[{"given":"Costanza","family":"Bogani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Bartalucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Tozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Associazione Italiana per la Ricerca sul Cancro AGIMM Gruppo Italiano Malattie Mieloproliferative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,1,31]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3322\/caac.20009","article-title":"Advances in understanding and management of myeloproliferative neoplasms","volume":"59","author":"AM Vannucchi","year":"2009","journal-title":"AC- A Cancer Journal for Clinicians"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","article-title":"New mutations and pathogenesis of myeloproliferative neoplasms","volume":"118","author":"W Vainchenker","year":"2011","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","article-title":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders","volume":"7","author":"RL Levine","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"LM Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Y Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort","volume":"112","author":"PA Beer","year":"2008","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","article-title":"Characteristics and clinical correlates of MPL 515W&gt;L\/K mutation in essential thrombocythemia","volume":"112","author":"AM Vannucchi","year":"2008","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/leu.2011.161","article-title":"Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients","volume":"25","author":"A Pardanani","year":"2011","journal-title":"Leukemia"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJM197406132902419","article-title":"Letter: Bone-marrow responses in polycythemia vera","volume":"290","author":"JF Prchal","year":"1974","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2006-10-054940","article-title":"The JAK2 V617F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera","volume":"110","author":"S Dupont","year":"2007","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2009-12-259747","article-title":"JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia","volume":"116","author":"J Li","year":"2010","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"A Mullally","year":"2010","journal-title":"Cancer Cell"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2009-12-257063","article-title":"Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice","volume":"116","author":"C Marty","year":"2010","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model","volume":"107","author":"G Wernig","year":"2006","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis","volume":"108","author":"C Lacout","year":"2006","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1371\/journal.pone.0000018","article-title":"Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F","volume":"1","author":"VM Zaleskas","year":"2006","journal-title":"PLoS ONE"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1182\/blood-2007-05-091579","article-title":"Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice","volume":"111","author":"S Xing","year":"2008","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice","volume":"111","author":"R Tiedt","year":"2008","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease","volume":"115","author":"H Akada","year":"2010","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"6891","DOI":"10.1158\/1078-0432.CCR-09-1298","article-title":"Combined inhibition of Janus kinase 1\/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity","volume":"15","author":"PC Liu","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"A Quintas-Cardama","year":"2010","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"S Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis","volume":"29","author":"A Pardanani","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, <etal>et al<\/etal>.. (2010) Durable Responses with the JAK1\/JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU). ASH Annual Meeting Abstracts 116: 313-.","DOI":"10.1182\/blood.V116.21.313.313"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis","volume":"366","author":"S Verstovsek","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis","volume":"366","author":"C Harrison","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","article-title":"Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies","volume":"29","author":"A Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1182\/blood-2009-05-222133","article-title":"Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells","volume":"114","author":"Y Wang","year":"2009","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"C James","year":"2005","journal-title":"Nature"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"11156","DOI":"10.1158\/0008-5472.CAN-06-2210","article-title":"Characterization of murine JAK2V617F-positive myeloproliferative disease","volume":"66","author":"TG Bumm","year":"2006","journal-title":"Cancer Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism","volume":"7","author":"JA Engelman","year":"2006","journal-title":"Nat Rev Genet"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"JA Engelman","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Maruani DM, Spiegel TN, Harris EN, Shachter AS, Unger HA, <etal>et al<\/etal>.. (2012) Estrogenic regulation of S6K1 expression creates a positive regulatory loop in control of breast cancer cell proliferation. Oncogene.","DOI":"10.1038\/onc.2011.657"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","article-title":"mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery","volume":"110","author":"D-H Kim","year":"2002","journal-title":"Cell"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1097-2765(03)00114-X","article-title":"G[beta]L, a Positive Regulator of the Rapamycin-Sensitive Pathway Required for the Nutrient-Sensitive Interaction between Raptor and mTOR","volume":"11","author":"D-H Kim","year":"2003","journal-title":"Molecular Cell"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1371\/journal.pbio.1000038","article-title":"Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2","volume":"7","author":"ME Feldman","year":"2009","journal-title":"PLoS Biol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nm.2091","article-title":"Effective and selective targeting of leukemia cells using a TORC1\/2 kinase inhibitor","volume":"16","author":"MR Janes","year":"2010","journal-title":"Nat Med"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.leu.2405043","article-title":"Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F","volume":"22","author":"K Shide","year":"2008","journal-title":"Leukemia"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1182\/blood-2005-06-2304","article-title":"AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation","volume":"107","author":"S Ghaffari","year":"2006","journal-title":"Blood"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood-2005-06-2516","article-title":"Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase\/AKT signaling pathway","volume":"107","author":"W Zhao","year":"2006","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2141.2009.07870.x","article-title":"Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms","volume":"147","author":"LF Grimwade","year":"2009","journal-title":"Br J Haematol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1634\/stemcells.2005-0062","article-title":"Mammalian target of rapamycin is required for thrombopoietin-induced proliferation of megakaryocyte progenitors","volume":"24","author":"AL Drayer","year":"2006","journal-title":"Stem Cells"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.exphem.2003.11.003","article-title":"Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera","volume":"32","author":"V Ugo","year":"2004","journal-title":"Exp Hematol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ccr.2009.10.015","article-title":"The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors","volume":"16","author":"M Hedvat","year":"2009","journal-title":"Cancer Cell"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"R Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"A Tefferi","year":"2007","journal-title":"Blood"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0002-9440(10)62056-1","article-title":"Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis","volume":"167","author":"AM Vannucchi","year":"2005","journal-title":"Am J Pathol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method","volume":"70","author":"T-C Chou","year":"2010","journal-title":"Cancer Research"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.exphem.2006.11.012","article-title":"Polycythemia vera is not initiated by JAK2V617F mutation","volume":"35","author":"RH Nussenzveig","year":"2007","journal-title":"Exp Hematol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","article-title":"Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms","volume":"113","author":"FH Grand","year":"2009","journal-title":"Blood"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study","volume":"29","author":"A Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood-2011-11-395228","article-title":"JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths","volume":"119","author":"A Tefferi","year":"2012","journal-title":"Blood"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood.V112.11.97.97","article-title":"A phase I study of TG101348, an orally bioavailanble JAK-selective inhibitor, in patients with myelofibrosis","volume":"112","author":"A Pardanani","year":"2008","journal-title":"Blood"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2011-01-330563","article-title":"Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1\/2 study in patients with myelofibrosis","volume":"118","author":"P Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","article-title":"Targeting the mTOR signaling network for cancer therapy","volume":"27","author":"F Meric-Bernstam","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"3902A","DOI":"10.1182\/blood.V114.22.3902.3902","article-title":"Genetic and pharmacologic targeting of STAT5\/Gab2\/PI3K\/mTOR signaling in a mouse myeloproliferative disease model","volume":"114","author":"G Li","year":"2009","journal-title":"Blood"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/leu.2010.131","article-title":"Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin","volume":"24","author":"G Li","year":"2010","journal-title":"Leukemia"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0054826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T15:01:25Z","timestamp":1595343685000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0054826"}},"subtitle":[],"editor":[{"given":"William","family":"Tse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,1,31]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0054826","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,31]]}}}